Central and regional hemodynamic studies were performed before and after the oral administration of 75 mg of hydralazine and/or 20 mg of isosorbide dinitrate in 15 patients with low-output congestive heart failure. Hydralazine increased mean cardiac output 17-25%, mean renal blood flow 19%, and limb blood flow 17% (all p < 0.05). Mean hepatic blood flow did not change significantly with hydralazine. Except for a small increase in cardiac output (6%, p < 0.05) at 30 minutes, isosorbide dinitrate did not significantly alter central, renal, hepatic or limb blood flow. Combining isosorbide dinitrate and hydralazine effected similar increases in cardiac output (17-24%, p < 0.05), renal (17%, p < 0.05) and limb (20%, p < 0.05) blood flow as those elicited by hydralazine alone. The combination did not significantly alter mean hepatic blood flow. Hydralazine, alone or combined with isosorbide dinitrate, increases renal and limb blood flow in congestive heart failure in proportion to the augmented cardiac output; isosorbide dinitrate alone does not alter blood flow to these regions. Neither drug (or combination) changes hepatic blood flow in this clinical setting.
VASODILATOR THERAPY has become an essential part of the management of congestive heart failure. The vasodilator combination of hydralazine and isosorbide dinitrate has attained popularity in the therapeutics of heart failure because the combined administration of these two drugs elicits a favorable reduction of both preload and afterload.'-4 Beneficial central hemodynamic effects have also been shown during submaximal exercise. 5 This study was designed to determine and compare the central and regional hemodynamic effects of hydralazine and isosorbide dinitrate, alone and in combination, in patients with chronic congestive heart failure.
Methods

Patient Population
Fifteen patients with moderately severe or severe congestive heart failure were studied. There were 12 males and three females, with a mean age of 57 years (range 24-68 years). All patients underwent diagnostic cardiac catheterization within 1 month of the study, and the cardiac diagnoses were congestive cardiomyopathy in nine patients and heart failure of ischemic origin in six patients. Eleven patients were classified as functional class IV and four patients as functional class III (New York Heart Association). All patients were receiving an oral digitalis preparation (digoxin, 0.25 mg daily in 11 patients and 0.125 mg daily in two patients; digitoxin, 0.1 mg daily in two patients) and a diuretic (furosemide, 80-280 mg daily) before the study; 11 of the 15 patients continued to have symptoms of cardiac failure at rest while receiving digitalis and furosemide. Two patients were taking 20 mg of isosorbide dinitrate orally every 6 hours. The diuretics and isosorbide dinitrate were discontinued in every patient at least 72 hours before study. Digitalis was continued throughout the study period. Protocol Each patient provided written informed consent before the onset of the study. After control central and regional hemodynamic data were obtained, eight of the patients received 20 mg of isosorbide dinitrate orally. Central hemodynamic studies were performed 30 minutes, 1, 2, 3 and 4 hours after the dose; regional hemodynamic determinations were made 1-2 hours after drug administration. On the next day and after control central hemodynamic data were obtained, these patients received 20 mg of oral isosorbide dinitrate and 75 mg of oral hydralazine simultaneously. Central hemodynamic studies were performed 30 minutes and hourly for 6 hours after drug administration; regional hemodynamic determinations were made 1-2 hours after the patient received the drugs. After control central and regional hemodynamic data were obtained, the remaining seven patients received 75 mg of oral hydralazine alone. Hourly central hemodynamic measurements were made for 6 hours and regional flow studies were obtained 1-2 hours after administration of the drug. There were no significant differences in the ages, diagnoses or control hemodynamic data (central and regional) of the two groups.
A flow-directed triple-lumen catheter was placed in the pulmonary artery before the onset of the study. This catheter, interphased with Electronics for Medicine M2 101 pressure amplification units, provided measurements of pulmonary artery and pulmonary capillary wedge (pulmonary artery occlusive) pressures. Cardiac outputs were determined in triplicate with the thermodilution technique, using an Instrumentation Laboratory 601 computer and 602 recorder. Systemic blood pressure was measured indirectly with a calibrated sphygmomanometer. The heart rate was determined from monitor recordings taken during cardiac output measurements. The following calculations were made: cardiac index (I/min/M2) = cardiac output/body surface area; stroke volume index (ml/beat/m2) = cardiac index/ heart rate; total systemic resistance (dyn-sec-cm-5) = mean systemic arterial pressure X 80/cardiac output; total pulmonary arterial resistance (dyn-sec-cm-5) = mean pulmonary artery pressure X 80/cardiac output; and pulmonary arteriolar resistance (dyn-sec-cm-5) = mean pulmonary artery pressuremean pulmonary capillary wedge pressure X 80/cardiac output.
Regional hemodynamic measurements included hepatic, renal and limb blood flow and resistances. Hepatic plasma flow was determined by indocyanine green clearance.6 7 Para-aminohippurate clearance was used to measure renal plasma flow. 8 The hepatic and renal plasma flow data were converted to blood flow values by dividing the plasma flow determinations by 1 -hematocrit. Limb blood flow (right upper extremity) was measured by venous occlusive plethysmography; a minimum of five measurements was taken and averaged for each limb blood flow determination (individual patient variance is less than 8%). The mean regional blood flow values for normal subjects obtained in our laboratory are hepatic blood flow = 1002 ml/min (n = 8, range 949-1082 ml/min, SD = 51, SEM = 18, variance = 5%), renal blood flow -1329 ml/min (n = 7, range 1250-1450 ml/min, SD = 70, SEM = 28, variance = 5%), and limb blood flow = 7.62 ml/ 100 ml/min (n = 12, range 6.8-9.1 ml/100 ml/min, SD = 0.72, SEM = 0.21, variance = 9%). Regional vascular resistances were calculated by dividing the mean arterial pressure by the regional flow value. Analysis of variance and the t test for paired data were used in the statistical analysis of the results.
Results
Central Hemodynamic Measurements
The control central hemodynarnic data of the two groups (one receiving hydralazine alone and the other receiving isosorbide dinitrate alone, then a combination of hydralazine and isosorbide dinitrate) are presented in table 1. Figure 1 illustrates the changes in the cardiac and stroke volume indexes and heart rate. Hydralazine, alone or with isosorbide dinitrate, increased the cardiac index significantly throughout the 6-hour measurement period. Isosorbide dinitrate increased the cardiac index only at 30 minutes after administration. Neither hydralazine nor isosorbide dinitrate, alone or in combination, affected heart rate significantly; as a result, the changes in stroke volume index reflected those of the cardiac index. The agents alone and in combination significantly decreased the 3B ). When isosorbide dinitrate was added to hydralazine, the early portion of the total pulmonary resistance response (30 mninute to 1 hour) was significantly lower than for hydralazine alone (p < 0.05); except for the 30-minute measure-ment, the entire curve of the combined drugs was significantly lower than that for isosorbide dinitrate alone (p < 0.05). Pulmonary arteriolar resistances were not different from control for these drugs, whether administered alone or in combination (fig. 3C).
Regional Hemodynamic Meagurements
The effects of these drugs on regional flow measurements are presented in table 2 and figures 4-6. Although the mean hepatic blood flow ( fig. 4 ) did not change significantly with hydralazine (when administered alone or with isosorbide dinitrate), five of the seven patients receiving hydralazine alone and six of eight patients receiving the combination increased their hepatic blood flow greater than 50 ml/min. Only one patient in the hydralazine group and two in the combination group decreased their hepatic blood flows more than 50 ml/min. Isosorbide dinitrate did not alter mean hepatic blood flow. There was no significant difference between the three mean hepatic blood flow responses. The mean hepatic vascular resistance was not significantly altered by hydralazine, isosorbide dinitrate, or the combination.
Hydralazine significantly increased mean renal X 0.60 Hydralazine significantly decreased the MPA P at 1 hour only. The addition of isosorbide dinitrate to hydralazine resulted in a greater decrease in the MPA P for the initial 2 hours than hydralazine alone. (B) All three dosing groups significantly decreased total pulmonary resistance (TPR). The addition of isosorbide dinitrate to hydralazine significantly decreased the 30-minute and 1hour values below the corresponding values for hydralazine alone. (C) Mean pulmonary arteriolar resistance (PAR) was not altered significantly by hydralazine, isosorbide dinitrate, or the combination, suggesting that mnost of the total pulmonary resistance changes (TPR, panel B) are secondary to a reduction in the PCWP. D ± SED = mean of the difference ± standard error of the difference. Although hydralazine exerts its effects primarily on the arteriolar vessels, this agent is capable of decreasing left ventricular filling pressure; the mechanism for this reduction in preload by hydralazine was not elucidated by this study. As previously reported,13 16 the primary central hemodynamic effect noted for orally administered isosorbide dinitrate was a significant reduction in PCWP and mean pulmonary artery pressure. A mild increase in stroke volume and cardiac output occurred 30 minutes after dosage; this suggests that isosorbide dinitrate, at this dose, is capable of shortlived arteriolar dilatation (afterload reduction). Improvement of the cardiac output with oral isosorbide dinitrate was also noted by Franciosa and col-leagues4' 16 using the 40-mg dose. This study and n 7 n58 HYDRALAZINE SOSORBIDE 75 mg 20 mg n 8 HYDRALAZINE 75mg ISOSORBIDE 20 mg FIGURE 6. Hydralazine, whether administered alone or with isosorbide, signifiantly increased limb blood flow and decreased limb vascular resistance. Limb blood flow and vascular resistance remained unchanged with isosorbide dinitrate. D ± SED = mean of the difference ± standard error of the difference. others1`4 show that combining isosorbide dinitrate with hydralazine offers an effective addition to the therapeutics of low-output congestive heart failure; with respect to improving central hemodynamics, the combination is generally better than either drug alone. Adding isosorbide dinitrate to hydralazine effected a significant enhancement of the responses in PCWP, mean pulmonary artery pressure, and total pulmonary vascular resistance over those of hydralazine alone. The improvement in these variables occurred within the first 2 hours after administration; thereafter, the addition of isosorbide dinitrate did not augment the hemodynamic responses elicited by hydralazine alone. A difference in the hemodynamic responsiveness of the two patient groups (hydralazine vs hydralazine-isosorbide dinitrate) cannot be excluded as a variable in these data.
Vasodilators (particularly afterload-reducing agents) increase cardiac output in congestive heart failure, but little information is available on the distribution of this augmented cardiac output. The hepatic and renal extractions of indocyanine green and para-aminohippurate, respectively, allow the clearance curves of these compounds to be utilized in the estimation of blood flow to the liver and kidneys. [6] [7] [8] The baseline hepatic, renal and limb blood flow values of our patient population were depressed below those of a normal population; the reduced baseline values are comparable to those compiled by Wade and Bishop17 in a similar patient population. The reduction in flow to these areas probably reflects a varying combination of a reduction in the central delivery (cardiac No 1, JANUARY 1981 output) of blood and vasoconstriction (via neural and humoral mechanisms18' 19) of the regional vascular beds.
Although five of the seven patients receiving hydralazine alone and six of eight patients receiving the combination increased their hepatic blood flow, neither hydralazine nor the hydralazine-isosorbide dinitrate combination significantly changed the mean values. Marks and Reynell20 found that hydralazine increased hepatic blood flow 65%; however, the study was performed in normal anesthetized dogs using bromsulphalein as an indicator and high-dose i.v. hydralazine (0.5-1.0 mg/kg). Isosorbide dinitrate did not change mean hepatic blood flow when measured during the preload-reducing period; mean cardiac output was also not altered during this time (1-2 hours after dosing). It is possible that isosorbide dinitrate may have significantly altered the hepatic flow during the transient combined afterload-preload reduction period (30 minutes after administration), during which time the cardiac output had increased and the total systemic resistance had decreased.
Hydralazine significantly increased renal blood flow in our heart failure propulation. Cogan et al. 12 and Judson and colleagues21 observed that i.v. hydralazine increased mean renal blood flow 126% and 92%, respectively, in patients with congestive heart failure; in both studies, the increase in mean renal blood flow was proportional to the increase in cardiac output. In our population, oral hydralazine increased the mean renal blood flow 19% at a time when the cardiac output increased 17-25%. Apparently, hydralazine does not preferentially dilate the renal vasculature in congestive heart failure. The increase in renal blood flow may in part explain the observation by Pierpont et al. 22 that hydralazine tends to improve renal function (specifically creatinine clearance) in patients with severe congestive heart failure. The individual renal flow response to isosorbide dinitrate varied considerably (table 2); this variation kept the mean change from achieving statistical significance, although it was 194 ml/min less than the control value. Hydralazine apparently overwhelmed the tendency of isosorbide dinitrate to compromise renal flow; the mean renal blood flow response of the hydralazine-isosorbide dinitrate combination was similar to that of hydralazine alone.
Hydralazine alone and the hydralazine-isosorbide dinitrate combination probably achieved a sizable proportion of its afterload reduction by dilating the arterioles of muscle and skin; limb blood flow increased and calculated limb vascular resistance decreased after the administration of these agents. Isosorbide dinitrate, also tested 1 hour after dosing, did not appear to affect limb blood flow or resistance. Figure 7 illustrates the relationship between the percent change in hepatic, renal and limb flow and the percent change in cardiac output elicited by hydralazine, isosorbide dinitrate and the combination. Values close to one were obtained for the flow/cardiac output ratio of these regions after hydralazine and the hydralazine-isosorbide dinitrate combination. FIGURE 7 . The relationship between the changes in regional flow and cardiac output (CO) are presented as a ratio ofpercent change flow to percent change cardiac output. The ratio approached or equaled unityfor hepatic blood flow (HBF), renal blood flow (RBF) and limb blood flow (LBF) after hydralazine and the hydralazine-isosorbide dinitrate combination. The ratio was considerably less than one for each variable after isosorbide dinitrate alone; the most dramatic decrease occurred in the RBF.
suggests that hydralazine and the combination increased flow to these structures in proportion to the increase in cardiac output; there is no evidence for preferential vasodilation or flow in these regions. The flow/cardiac output values for the three areas were considerably less than unity after isosorbide dinitrate alone. Because the cardiac output (1-2 hours after isosorbide) was not significantly different from control, a redistribution of peripheral flow is suggested for this drug. Unfortunately, the blood flow to certain areas of extreme importance (e.g., brain, coronary arteries) do not lend themselves to precise quantitation without invasive methods.
The central and regional hemodynamic responses were obtained at one dose for each agent. Previous work from this laboratory2. showed that both the direction and the extent of regional flow changes are related not only to the drug administered, but also to the dose of that agent. Oral isosorbide dinitrate at doses of 40 mg and 60 mg could have a different effect 108 CIRCULATION HYDRALAZINE AND ISOSORBIDE DINITRATE/Leier et al.
(direction and/or extent) on regional flow. A 100-mg dose of hydralazine augments the magnitude of the hepatic, renal and limb flow responses compared with the 75-mg dose. 23 The study of the regional distribution of blood flow during the pharmacologic manipulation of heart failure will provide additional information on peripheral responses in heart failure, will assist in the formulation of the rationale for drug selection based on central and regional hemodynamic effects, and will supply information on the disposition and clearance of concomitantly administered drugs. Knowing that a particular drug does not decrease flow to a specific region or that an agent may be selected to improve flow to a compromised organ (e.g., liver, kidney) should facilitate the overall management of the patient with heart failure.
